JP2024532503A5 - - Google Patents
Info
- Publication number
- JP2024532503A5 JP2024532503A5 JP2024514046A JP2024514046A JP2024532503A5 JP 2024532503 A5 JP2024532503 A5 JP 2024532503A5 JP 2024514046 A JP2024514046 A JP 2024514046A JP 2024514046 A JP2024514046 A JP 2024514046A JP 2024532503 A5 JP2024532503 A5 JP 2024532503A5
- Authority
- JP
- Japan
- Prior art keywords
- glp
- target polypeptide
- terminus
- fusion protein
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111026970 | 2021-09-02 | ||
| CN202111026970.5 | 2021-09-02 | ||
| PCT/CN2022/116513 WO2023030444A1 (zh) | 2021-09-02 | 2022-09-01 | Glp-1/gip双靶多肽、融合蛋白及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024532503A JP2024532503A (ja) | 2024-09-05 |
| JP2024532503A5 true JP2024532503A5 (cg-RX-API-DMAC7.html) | 2025-08-14 |
Family
ID=85411955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024514046A Pending JP2024532503A (ja) | 2021-09-02 | 2022-09-01 | Glp-1/gipデュアルターゲット型ポリペプチド及び融合タンパク質並びにこれらの適用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250223331A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4410827A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024532503A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115850437A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023030444A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114617956B (zh) * | 2020-12-10 | 2023-10-03 | 江苏中新医药有限公司 | 一种高效降糖的蛋白质药物 |
| KR20240007251A (ko) | 2021-05-13 | 2024-01-16 | 카모트 테라퓨틱스, 인크. | G-단백질 결합 수용체의 조절제 |
| KR20250140132A (ko) * | 2023-01-18 | 2025-09-24 | 상하이 민웨이 바이오테크놀로지 씨오 엘티디 | 삼중 활성을 갖는 융합 단백질 및 그 용도 |
| WO2025049610A1 (en) * | 2023-08-28 | 2025-03-06 | Shattuck Labs, Inc. | Multi-action peptides |
| US20250270274A1 (en) * | 2024-02-26 | 2025-08-28 | Serpentide Inc. | Super long-lasting glp1 or glp1/gip analogue drug for type-2 diabetes and obesity |
| CN120829494A (zh) * | 2024-04-18 | 2025-10-24 | 苏州星曜坤泽生物制药有限公司 | 一种glp-1gip类似物、fgf21蛋白、三功能蛋白及其应用 |
| WO2026046352A1 (zh) * | 2024-08-30 | 2026-03-05 | 石药集团巨石生物制药有限公司 | 一种gip/glp-1受体共激动剂及其应用 |
| WO2026076425A1 (en) | 2024-10-04 | 2026-04-09 | Biodrive, Inc. | Oral biodelivery platform |
| CN118955739B (zh) * | 2024-10-17 | 2025-02-18 | 华南理工大学 | 一种双靶点受体激动剂融合蛋白及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2558842T3 (es) * | 2008-06-17 | 2016-02-09 | Indiana University Research And Technology Corporation | Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad |
| WO2013003449A2 (en) * | 2011-06-27 | 2013-01-03 | Phasebio Pharmaceuticals, Inc. | Methods of treatment with glp-1 receptor agonists |
| CA2872314C (en) * | 2012-05-03 | 2021-08-31 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| MX2014015557A (es) * | 2012-06-21 | 2015-02-24 | Univ Indiana Res & Tech Corp | Polipeptidos de fusion de region fc de polipeptido de ligando receptor de incretina y conjugados con función efectora fc alterada. |
| CA2929459C (en) * | 2013-11-06 | 2022-05-03 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| WO2016131893A1 (en) * | 2015-02-18 | 2016-08-25 | Medimmune Limited | Incretin fusion polypeptides |
| CN110684082B (zh) * | 2019-10-08 | 2021-12-10 | 江苏诺泰澳赛诺生物制药股份有限公司 | Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途 |
| WO2021083306A1 (zh) * | 2019-10-31 | 2021-05-06 | 东莞市东阳光生物药研发有限公司 | Glp-1/gcg双受体激动剂多肽 |
| CN111111264A (zh) * | 2019-12-31 | 2020-05-08 | 杭州九源基因工程有限公司 | 制备多肽步骤中色谱固定相的再生方法 |
| CN113150172B (zh) * | 2021-04-28 | 2023-09-22 | 中国药科大学 | Glp-1r/gipr双靶点激动剂融合蛋白及其制备方法与应用 |
-
2022
- 2022-09-01 EP EP22863579.3A patent/EP4410827A4/en active Pending
- 2022-09-01 US US18/688,258 patent/US20250223331A1/en active Pending
- 2022-09-01 JP JP2024514046A patent/JP2024532503A/ja active Pending
- 2022-09-01 CN CN202211067063.XA patent/CN115850437A/zh active Pending
- 2022-09-01 WO PCT/CN2022/116513 patent/WO2023030444A1/zh not_active Ceased